Exploration of Immune Tolerance and Treatment for Esophageal Cancer
10.3971/j.issn.1000-8578.2023.23.0790
- VernacularTitle:食管癌免疫耐受及治疗方法的探索
- Author:
Siyuan XING
1
;
Qingxia FAN
;
Zhengzheng SHAN
;
Xiangrui MENG
;
Feng WANG
Author Information
1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
- Publication Type:Research Article
- Keywords:
Cancer immune evasion;
Tumor immune microenvironment;
Regulatory T cell;
Cancer-associated fibroblast;
Cancer immunotherapy;
Targeted therapy
- From:
Cancer Research on Prevention and Treatment
2023;50(12):1174-1179
- CountryChina
- Language:Chinese
-
Abstract:
Monoclonal antibody drugs that inhibit programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) have been widely used in esophageal cancer (EC) and yielded significant therapeutic responses. However, only a few patients obtain lasting clinical benefits due to primary or acquired drug resistance, and new treatment schemes are urgently needed. The tumor immune microenvironment is the main factor that affects patients' response to immunosuppressive agents. This article will discuss the role of immunosuppressive cells and non-cellular components in the immune process to provide ideas for the next research direction of EC.
